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Gastrointestinal tractThe aimof this review is to examine the relationship between geneticallymodiﬁed (GM) crops and health, based on
histopathological investigations of the digestive tract in rats. We reviewed published long-term feeding studies of
crops containing one or more of three speciﬁc traits: herbicide tolerance via the EPSPS gene and insect resistance
via cry1Ab or cry3Bb1 genes. These genes are commonly found in commercialised GM crops. Our search found 21
studies for nine (19%) out of the 47 crops approved for human and/or animal consumption.We couldﬁndno studies
on the other 38 (81%) approved crops. Fourteen out of the 21 studies (67%) were general health assessments of the
GM crop on rat health. Most of these studies (76%) were performed after the crop had been approved for human
and/or animal consumption, with half of these being published at least nine years after approval. Our review also
discovered an inconsistency in methodology and a lack of deﬁned criteria for outcomes that would be considered
toxicologically or pathologically signiﬁcant. In addition, therewas a lack of transparency in themethods and results,
which made comparisons between the studies difﬁcult. The evidence reviewed here demonstrates an incomplete
picture regarding the toxicity (and safety) of GM products consumed by humans and animals. Therefore, each
GM product should be assessed on merit, with appropriate studies performed to indicate the level of safety associ-
ated with them. Detailed guidelines should be developed which will allow for the generation of comparable and
reproducible studies. This will establish a foundation for evidence-based guidelines, to better determine if GM
food is safe for human and animal consumption.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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1.1. Background
Genetically modiﬁed (GM) or transgenic crops have been grown for
human and animal consumption since the 1990s (Clive and Krattiger,
1996). There are currently over 200 different GM crops with various
traits approved for human and animal consumption in many countries
(ISAAA, 2013). Despite this, feeding studies examining the effects of
GM crops on animal and human health are relatively scarce
(Domingo, 2000; Domingo and Bordonaba, 2011; Snell et al., 2012).
1.2. Unintended effects and the need for animal feeding studies
The twomost commonmethods of producing GM crops are through
Agrobacterium-mediated transformation and microparticle bombard-
ment (also known as microparticle acceleration or biolistics) (Wilson
et al., 2006). A common criticism is that these processes are imprecise.
In both processes, the insertion site of the new DNA is random
(Altpeter et al., 2005; Wilson et al., 2006) and more than one copy of
the DNA fragment may be inserted into the target genome (Christou,
1992; Gasson, 2003). This can affect gene expression in a positive or
negative manner, for example, by causing gene suppression or gene si-
lencing (Altpeter et al., 2005; Dai et al., 2001). In microparticle bom-
bardment, the extra copies of the inserted DNA can be scrambled,
inverted or incomplete (Altpeter et al., 2005). In addition, in micropar-
ticle bombardment, the site of insertion may undergo further recombi-
nation (Altpeter et al., 2005; Christou et al., 1988;Windels et al., 2001).
For these reasons, the toxicity or nutritional value of theGMcrop should
be assessed as a whole.
Transgenic crops are produced through the insertion of a gene cas-
sette, which consists of the desired trait genes, as well as several other
genes such as viral promoter and marker genes. These genes tend to be
truncated or shortened versions, which may even have gene sequence
changes (ISAAA, 2013; Padgette et al., 1995; Vaeck et al., 1987). The effect
of these genes acting together is not often determined or even required
(FAO/WHO, 2000; FSANZ, 2007).
At present, establishing substantial equivalence is the only generally
required safety assessment (FAO/WHO, 2000; FSANZ, 2007). Substantial
equivalence relies on the premise that the safety of GM food can be
assessed through a comparison with compounds or organisms of
known safety. The purpose of the test for substantial equivalence is to
identify possible hazard areas, which become the focus of further assess-
ment (FSANZ, 2007; König et al., 2004). The test for substantial equiva-
lence examines the individual characters and not the GM crop as a
whole. For example, it assesses the toxicity of the new protein the plant
has been designed to produce, such as an insecticidal protein or a protein
conferring herbicide tolerance. Based on the safe history of consumption
of that protein in its wild-type form, the protein is deemed safe (Kuiper
et al., 2001). If the test for substantial equivalence shows no differences
outside what could be obtained through natural variation, then food reg-
ulators may not require further examinations (Schilter and Constable,
2002). This type of general safety assessment does not consider that the
genes present in the novel food may be additional or different from
what is anticipated (Padgette et al., 1995; Vaeck et al., 1987; Wilson
et al., 2006). It does not take into account the alteration of the protein
gene sequence prior to insertion or the possibility that the protein gene
sequence may have been altered due to the transformation process, al-
though the latter has recently been incorporated into the European
Food Safety Agency (EFSA) assessment processes (EFSA, 2008). Hence,
we argue that GM crops should undergo thorough safety evaluations
that do not simply consider the GM food as being composed of several
substances of known safety, but as a novel entity, the safety of which
needs to be evaluated as a whole.
Double- or multi-trait stacked crops are becoming more and more
common (Clive, 2013). These are obtained either through more thanone trait being inserted into one crop, or through cross-breeding of
two or more GM crops (ISAAA, 2013). Many food regulators do not re-
quire any studies to be done on crops containing several stacked
genes if all the genes in the stack have previously been individually ap-
proved for use in the same kind of plant (EFSA, 2010; FSANZ, 2010).
However, the effect of two or more traits acting together is unknown.
For example, two insecticidal proteins, when ingested together, may
have a potentiating or synergistic effect (Schnepf et al., 1998). In real-
life scenarios, animals and humansmost probably consumeGMmateri-
al and products of various traits in a single meal. Therefore, it is sug-
gested that long-term animal feeding studies be performed to
investigate the toxicity of crops possessingmore than one trait to inves-
tigate the toxicity of feed containing more than one GM component.
1.3. The importance of studying the gastrointestinal tract
The digestive tract is the ﬁrst site of contact for any ingested com-
pound. It follows that if a compound is toxic, the ﬁrst signs of toxicity
may be visible in the gastrointestinal (GI) tract. Furthermore, since the
stomach and the intestines are the sites of longest residence for any
ingested product, these should become the most important sites for
the evaluation of an ingested compound's toxicity. It is difﬁcult to assess
damage to the digestive tract purely on macroscopic grounds (Morini
and Grandi, 2010), therefore a histopathological analysis should be
part of the investigation.
2. Methods
Thepurpose of this literature reviewwas to examine the relationship
between GM crops and histopathological observations in rats. The
search only included crops possessing oneormore of three speciﬁc traits
which are commonly found in commercialised GM crops: herbicide tol-
erance via the EPSPS gene, and insect resistance via cry1Ab or cry3Bb1
genes. A list of crop event names was ﬁrst generated (Table 1) based
on GM approval databases (CERA, 2012; FSANZ, 2011b; ISAAA, 2013)
and publications, such as literature reviews (Domingo, 2007; Domingo
and Bordonaba, 2011; Magaña-Gómez and De La Barca, 2009; Pusztai
et al., 2003; Snell et al., 2012). The search used PubMed, Google Scholar
and Embase to ﬁnd studies that were published before April 2013. The
searchwas restricted to published studies. Reports, such as EFSA reports,
were not included since they do not contain detailed histopathological
results. The keywords used were rat, rats, rattus and the speciﬁc crop
event line name (Table 1). To make results comparable with each
other, the search was limited to long-term rat feeding studies of no
less than 90 days duration. The search excludedmultigenerational stud-
ies, unless there was a histopathological investigation in the ﬁrst gener-
ation of rats. No language limit was set. For non-English publications,
help was obtained with their translation and accurate understanding.
3. Results
The search yielded 21 published studies (Table 2) with an additional
two re-analyses of raw data of some of these studies (de Vendomois
et al., 2009; Seralini et al., 2007). The re-analyses concentrated only on
the blood, serum and urine test results. (These publications are not
counted nor listed in the tables or ﬁgures since they are not original
feeding studies). Eighteen (86%) out of the 21 studies investigated
crops that have been approved for human and/or animal consumption
somewhere in the world (Table 1). These 18 studies investigated only
nine out of the 47 approved GM crops (19%) known to possess at least
one of the traits of interest. No published rat-feeding studies could be
found for the remaining 38 (81%) approved crops. Of all the 21 studies
found, 12 (57%) generally assessed the long-term effect of GM feed on
rat health (Hammond et al., 2004, 2006a,b; Healy et al., 2008; Qi et al.,
2012; Sakamoto et al., 2007, 2008; Schrøder et al., 2007; Seralini et al.,
2012; Tutel'ian et al., 2008, 2010; Wang et al., 2002), whilst seven
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reactions (Kroghsbo et al., 2008; Teshima et al., 2000), effects of a GM
diet on the blood, urine and liver (Tutel'ian et al., 1999, 2001), fate of
the inserted DNA (Zhu et al., 2004), comparison of GM soy versus con-
ventional soy and its nutritional impact (Daleprane et al., 2009), and
the impact of a soy diet, be it GM or non-GM, on aortic wall remodelling
(Daleprane et al., 2010).
The majority of the studies found were published in the last decade
(Figs. 1 and 2). The earliest studywas published in 1995, whichwas of a
GM tomato that was probably never commercially grown (Noteborn
et al., 1995). The study investigated the effect of the insecticidal protein
cry1Ab, on its own or in the GM tomato, on various mammalian diges-
tive systems. However, at the time of publication, the researchers had
not yet performed a histopathological analysis of the effect of the GM
crop on rat health.
The earliest published study on an approved crop was in 1999
(Tutel'ian et al., 1999) (Fig. 2), which was four years after that crop
had been approved for human and animal consumption. This study
only investigated the blood, urea and the liver of animals fed GM soy.
The ﬁrst study that generally assessed the long-term effect of GM feed
on rat health was in 2002 (Wang et al., 2002). It investigated a GM
rice (KMD1) that is approved for commercial use only in China. This ap-
proval was granted seven years after the Wang et al. (2002) study was
published (Chen et al., 2011). Two other studies also investigated this
crop (Kroghsbo et al., 2008; Schrøder et al., 2007), both of which were
published prior to the approval. The remaining 16 (76%) published
studies found in this reviewwere published after the crops had been ap-
proved for human and/or animal consumption. Half of these were per-
formed at least nine years after the approval was granted.
Five studies based their methodology on the Organisation for Eco-
nomic Cooperation and Development (OECD) guidelines for the testing
of chemicals— OECD Guideline 408: repeated dose 90 day oral toxicity
study (OECD, 1981, 1998). Fourteen studies indicated that the digestive
tract was investigated histopathologically, but no details were given as
to what analyses were performed. The only details most often provided
were that tissue samples were processed, parafﬁn embedded, and sec-
tionswere cut and stainedwith haematoxylin and eosin (H&E). Sections
were then assessed using light microscopy (LM). Seralini et al. (2012)
indicated that sections were stained with HES, but failed to specify
whether this abbreviation meant haematoxylin and eosin,
haematoxylin eosin safran/saffron or haematoxylin erythrosine saffron
stain. Seralini et al. (2012) also indicated that if any tumours were ob-
served, they were processed for transmission electron microscopy
(TEM). There was no mention if tumours were observed in the GI tract.
Six of the studies indicate that a pathologist or veterinary pathologist
performed the histopathological analysis. Five studies provided some
formof results of their analyses,whilstmost limited their results section
to a statement that overall there were no treatment-related or
diagnostically-signiﬁcant observations.
Overall, all the studies examining the GI tract concluded that there
were no toxicological or pathological changes observed that could be re-
lated to feeding GM crops to rats.
4. Discussion
The digestive tract is the ﬁrst site of contact with the body of any
ingested food. Therefore, if a novel food is toxic to the body, signs of tox-
icitymay be present in the GI tract. Often these changesmay only be de-
tectable by histopathological analysis and notmacroscopic observations
(Morini and Grandi, 2010).
4.1. Review of the methods
Whilst 14 out of the 21 studies reviewed (67%) indicated that organs
of the digestive tract were collected for histopathological examination,
none of the methods sections in these publications included any detailsas to the nature of the histopathological examination. Several of the
studies (Hammond et al., 2004, 2006a,b; Healy et al., 2008; Qi et al.,
2012; Zhu et al., 2004) simply stated that a pathologist or veterinary pa-
thologist performed the analysis, but no mention was given as to what
these analyses entailed, for example what pathological parameters
were used or what was measured and why. The exception appears to
be a study by Teshima et al. (2000) who stated that the morphology
of the small intestine mucosa was assessed, in particular the composi-
tion of goblet cells and intraepithelial lymphocytes. According to the au-
thors, the analysis was based on a chapter in an immunotoxicology
textbook (Kawabata, 1996). However, that chapter did not mention
the purpose or even how the investigation of the small intestine should
appear. In particular, it did not include the deﬁnition of what constitutes
abnormal or diseased, such as, what changes in goblet cell population
would indicate a pathology.
A paper that appears to be well-structured and thorough was the
Tutel'ian et al. (2008) study published in Russian. The methods section
clearly stated that the morphometric analysis of the internal organs
was conducted according to textbook guidelines (Avtandilov, 1982,
1990) and results were compared according to guidelines set out by
Stefanov (1985). The two Russian textbooks (Avtandilov, 1982, 1990)
are manuals on how to conduct quantitative research to obtain amean-
ingful assessment of morphological changes. In other words, the
Tutel'ian et al. (2008) study appears to be thorough andwell set out, es-
pecially since detailed results are provided for the analyses. However,
the publication lacks basic information. It does not specify the number
of rats used in the study and it does not list which organswere collected
for the histopathological analyses. Results seem to imply that the ileum
was the only section of the GI tract to be analysed. A more thorough
studywould have investigated other sections of the GI tract tomore ac-
curately ensure that the GM crop did not have any adverse effects.
Another Russian study (Tutel'ian et al., 2010) also appears to be
properly conducted. Its safety assessment is based on the Tutel'ian
et al. (2008) study, which implies that the same rigorousmorphometric
analysis was also utilised. However, even this publication lacks key in-
formation. For example, the paper indicated that the morphometric
analysis was conducted on the small intestine and colon, but results
were only reported for the small intestine. In addition, the publication
does not specify which section of the small intestine these results per-
tain to. This lack of detail in both Russian papers makes it difﬁcult to de-
termine the veracity of the results. It alsomakes it difﬁcult to reproduce
and further the study or to compare these studies to others. Indeed, in
all the published papers, a lack of uniformity in the analytical approach
as well as documentation of the methods and results makes any com-
parison or assessment of adequacy or inadequacy of the studies difﬁcult.4.2. Selection of endpoints
A major ﬂaw in all the studies reviewed was the lack of any deﬁ-
nition of toxicity or signs of pathology. Of all the studies generally
assessing rat health on a GM diet, not one explained how the study
would adequately show that the crop is safe for human and/or ani-
mal consumption. Furthermore, all the studies reviewed failed to
justify or give reason for the choice of methods used. Yet, most stud-
ies concluded that the investigation did not reveal any meaningful
differences between animals fed the GM or non-GM feed. One
study even stated that “since no meaningful differences were ob-
served, no further microscopic examinations were deemed neces-
sary” (Hammond et al., 2004). However, the absence of meaningful
differences in a preliminary investigation does not mean that further
analysis would not ﬁnd meaningful differences. In addition, the au-
thors did not support this statement with proof since they provided
few details as to what their microscopic examinations entailed or
found. Therefore, they give very little evidence that their study ade-
quately assessed the safety of consuming the GM crop.
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observed were not diagnostically signiﬁcant, were within the normal
range, or are common to this strain and age of rat. The six studies thatTable 1
Literature search: list of GM crop event names thatwere used in the search for published studie
of publications found per event.
Crop type Event name (other name and/or code name)a,b Number o
Roundup Ready (RR) or glyphosate-tolerant crops:
Crops containing EPSPS genes
Alfalfa/Lucerne J101 (MON-00101-8) 0
J163 (MON-00163-7) 0
Canola GT200 (RT200, MON89249-2) 0
GT73 (RT73, MON737) 0
MON88302 (MON-88302-9) 0
ZSR500 (ZSR500 x GT73) 0
ZSR502 (ZSR502 x GT73) 0
ZSR503 (ZSR503 x GT73) 0
Corn/Maize GA21 (MON00021-9) 1d
HCEM485 0
NK603 (MON-00603-6) 2
MON832 0
MON87427 (MON-87427-7) 0
Cotton GHB614 (BCS-GH205) 0
MON1445 (MON1445-2) 0
MON1698 (MON89383-1) 0
MON88913 (MON88913-8) 0
Creeping bentgrass ASR368 (SGM-36800-2)e 0
Potato RBMT22-082 (RBMT22-82, NMK-89896-6) 0
RBMT22-186 0
RBMT22-238 0
RBMT22-262 0
Soybean 40-3-2 (GTS 40-3-2, MON04032-6) 4
FG-72 (MST-FG072-2) 0
MON87705 (MON87705-6) 0
MON87708 (MON87708-9) 0
MON87769 0
MON89788 (MON89788-1) 1f
Glyphosate-tolerant g 3g
305423 x 40-3-2 (DP305423 x GTS40-3-2,
DP-305423-1 x MON-04032-6)b
1
Sugar beet GTS B77 (T9100152, SY-GTSB-77-8) 0
H7-1 (KM71-4) 0
Wheat MON71800 (MON-71800-3) 0
Insect resistant or Bt crops:
Crops containing Cry3Bb1 and EPSPS genes
Corn/Maize MON88017 (MON-88017-3)h 2h
Crops containing Cry3Bb1 genes
Corn/Maize MON863 (MON-00863-5) 1
Crops containing Cry1Ab genes
Corn/Maize 5307 (SYN-05307-1) 0
Bt10 0
Bt11 (x 4334CBR, x 4634CBR. SYN-Bt011-1) 0
Bt176 (176, SYN-EV176-9) 0
Cotton COT67B (IR67B, SYN-IR67B-1,) 0
GFM Cry1A (GTL-GFM311-7) 0
GK12 0
T303-3 (BCS-GH003-6) 0
T304-40 (BCS-GH004-7) 0
Rice Tarom molaii + cry1ab 0
KMD 1 rice (Kemingdao 1, TR30) 3
GM Shanyou 63 0
Hauhui-1/TT51-1 0
Tomato RLE13-0009i 1
RLE6-1000i 0
Crops containing Cry1Ab and EPSPS genes
Corn/Maize MON801 (MON80100) 0
MON802 (MON-80200-7) 0
MON809 (PH-MON-809) 0
MON810 (MON-00810-6) 2d
Number of GM crop event lines studied 10f,h
Total number of GM crop event lines 53f,h
Total number of published studies found 21made this remark gave little evidence to support this conclusion
(Hammond et al., 2004, 2006a,b; Healy et al., 2008; Qi et al., 2012;
Teshima et al., 2000). Most gave no evidence at all. For example, Qi et al.s. Year of approval for animal and/or human consumption of each event name and number
f published long-term rat feeding studies Year approved for food and/or feedc
2004
2004
1997
1994
2012
1997
1997
1997
2000
2012
2000
1996
2012
2008
1995
1995
2005
2003
1998
1998
1998
1998
1995
2012
2011
2011
2011
2007
NA
2010
1998
2003
2004
1996
2001
2012
1995
1996
1995
2009
Cultivation only (2006)
Cultivation only (1997)
Cultivation only (2012)
2010
2004
2009
2009
Cultivation only (2009)
No approval info.i
No approval info.i
1996
1997
1996
1996
9 approved
47 approved
19 approved
427I.M. Zdziarski et al. / Environment International 73 (2014) 423–433(2012) referenced a study by Tang et al. (2012) to support their notion
that “microscopic observations occurred spontaneously in Sprague–
Dawley rats of this age.”However, the referenced studymade nomention
of microscopic observations occurring spontaneously and the study did
not even use Sprague–Dawley rats.
A very common statement found in the reviewed studies was that
since the lesions or changes were observed in both groups, they were
not deemed to be diet-related (Healy et al., 2008; Sakamoto et al., 2007,
2008; Wang et al., 2002). For example, in two studies (Hammond et al.,
2006b; Sakamoto et al., 2007), there was a brief mention of gastric
gland dilatations being observed in both the GM and non-GM fed groups.
Gland dilatations can occur in aged rats (Frantz et al., 1991), but they can
also be a pathological occurrence for example in alendronate-induced in-
jury (Şener et al., 2004), ulcer healing (Tarnawski et al., 1991) or underly-
ing neoplastic lesions (Frantz et al., 1991). In these pathologies, the
dilatations are large, they may sometimes extend into the submucosa
and theymay becomedysplastic (Kikuchi et al., 2010). In the twopublica-
tions (Hammond et al., 2006b; Sakamoto et al., 2007), no speciﬁc details
are mentioned, for example, the size of these dilatations, whether the
treatment group had larger dilatations than the other group, whether
the affected area was more widespread in one group than the other, or
if the cells lining the dilatations had a speciﬁc staining property or
shape common only to one group. If a pathology is seen, regardless of
whether it occurs in both groups, further analysis should be performed
to determine the nature of the occurrence and to completely rule-out dis-
ease. Furthermore, whilst the incidence of a pathology may be equal in
both groups, the degree or severity may vary. Therefore, it is always im-
portant to record and report the severity of a pathology. For example,
an animal may be prone to a certain pathology (e.g. Sprague–Dawley
rats are known to spontaneously develop certain neoplastic lesions)
(Chandra et al., 1992; Kaspareit and Rittinghausen, 1999), but it is possible
that the GM component may increase the severity or risk of this develop-
ment. In addition, the type of crop fedmay cause a pathology. For example,
soy is known to have adverse effects on bone and the digestive tract
(Godlewski et al., 2006;Piastowska-Ciesielska andGralak, 2010). Therefore,
feeding soy would naturally cause changes to the gut, but the GM compo-
nentmay increase the severity of these changes. Hence, detailed histopath-
ological andmorphometric analyses are needed to completely rule out the
GM crops' involvement in the development of the lesion or pathological
condition. In other words, it is not sufﬁcient to say that the GM food is
safe if incidences of a pathology or lesion are equal in both groups. Further
testing should be carried out to completely rule out the GM component's
involvement in the development of the pathological incidence(s).
Another common conclusion made was that no changes were seen
that could be considered treatment, test-article, or test-substance related,
or toxicologically relevant. However, the six studies that made this con-
clusion did not deﬁne treatment-related or toxicologically relevant.
(Hammond et al., 2006a,b; Healy et al., 2008; Qi et al., 2012; Wang
et al., 2002; Zhu et al., 2004). Therefore, they did not provide clearly de-
ﬁned criteria by which to judge if a given tissue was normal or not, andNotes to Table 1
a Each line contains one crop. Succeeding names are the other names given to the crop even
b GM crop hybrids are not listed in the table, unless the crop is listed in databases as a single
publication was found during the search for publications.
c The year that the crop was ﬁrst approved somewhere in the world for human and/or anim
d One publication contained results for two feeding studies— one on MON810 corn and the ot
published studies.
e ASR368 creeping bentgrass is solely intended for the production of turfgrass in golf course
f One study generating two published reports. The ﬁrst reported the results for the analysis of m
et al., 2010). The second reported the allergenic potential and immunoreactivity, aswell as looked fo
been counted as one published study.
g TheGMcrop or event namewasnot listed in three publications. TheGMcrop studied contai
event line in the ﬁnal number of GM crop event lines studied nor in the total number of GM cr
h One study generating two published reports. The ﬁrst reported the results for the analysis
(Tutel'ian et al., 2008). The second reported the allergenic potential and immunoreactivity, asw
study, they have been counted as one published study.
i The Bt tomatoes may never have been released. The feeding study by Noteborn et al. (1995
investigated in the rat, but in other laboratory animals.if abnormal, whether the abnormality was toxicologically relevant
and/or treatment-related. Some food regulators, such as Food Stan-
dards Australia New Zealand (FSANZ, 2007) describe GM food as
novel food. In other words, they recognise that no deﬁnition yet ex-
ists for toxicologically relevant or test-substance related changes.
However, by applying the test for substantial equivalence, food reg-
ulators argue that an existing compound or plant of known toxicity
can be used to evaluate or predict the action of a novel compound or
food such as a GM crop (FSANZ, 2007; König et al., 2004; Kuiper and
Kleter, 2003). If so, deﬁning what is toxicologically relevant or test-
substance related should be a simple task. Consequently, the pub-
lished studies should have been able to supply the deﬁnition and
evidence that the results showed no treatment-related or toxico-
logically relevant changes.
If an existing compound can't predict the action of a GM crop on an-
imal health, further investigationwould be necessary. Known toxicity of
single components of the GM crop may not deﬁne an overall toxicity of
the entire crop. It is not clear whether the test for substantial equivalence
is sufﬁcient because it does not take into account the changes that could
arise from the transformation process: (1) through the random insertion
of the genes, (2) through the genetic alterations made to the transferred
genes as a result of the transformation process, (3) through the genetic
alterations made to the plant as a result of the transformation process
(Wilson et al., 2006), (4) through the insertion of several traits or genes
into one crop or (5) through the alteration made to the genes encoding
the desired trait prior to the transformation.
4.3. Lack of transparency in results
Several of the reviewedpublications donot adequately report their re-
sults. Some do not even provide any results (Table 2). For example, the
paper by Zhu et al. (2004) not only lacks a detailed methods section,
but also limits its histopathological results to a simple statement that “al-
though some slight lesions (such as slightly dilated alveolus cavity, pelvic
dilation of the kidneys, slight disconnection of myocardial ﬁbre and col-
lapse of jejunumvilli) occurred in rats examined, theywerenot treatment
related.” Such a statement could imply that other changesmay have been
observed, but are not reported. Furthermore, this study does notmention
the incidence or severity of any histopathological changes, including
whether they occurred in the treatment or non-treatment group. For ex-
ample, they do not state how many rats showed collapsed jejunum villi
andwhether theseweremore prevalent in one group orwhether the col-
lapsed villi were more severe in one group. A lack of transparency in re-
sults does not allow other researchers to judge whether a certain
ﬁnding is pathologically relevant. Another paper (Tutel'ian et al., 2010) in-
dicated that they had performed a morphometric analysis of the small
and large intestines, but they did not report the colon results. A lack of
transparency is also evident in two other studies: 1) Hammond et al.
(2004) report the ﬁndings from “only those tissues with an incidence of
2 or more ﬁndings”; and 2) Healy et al. (2008) state that “ﬁndings int name and/or the crop's code name.
event name. An exception is the GM soybean line 305423 × 40-3-2, since a feeding study
al consumption.
her on GA21 corn. As these are two separate feeding studies they have been counted as two
s, but it can be used as livestock feed (CERA, 2012).
orphological, haematological, and biochemical parameters and system biomarkers (Tutel'ian
r signs of genotoxicity (Tyshkoet al., 2010). Since the reports are of the samestudy, theyhave
ned the EPSPS gene, which confers glyphosate tolerance. Thiswas not counted as a separate
op event lines.
of morphological, haematological, and biochemical parameters and system biomarkers
ell as looked for signs of genotoxicity (Tyshko et al., 2008). Since the reports are of the same
) looked at the effect of only RLE13-0009 on the rat. The effect of RLE6-10001 was not
Table 2
Summary of published studies in order of trait and publication date.
Study GM component
(event or crop name)
Duration Purpose of study No. of rats/
treatment group
Histopathology performed
and analysis of GI tract
Histopathological results
for GI tract
Feeding study
guidelines
EPSPS
Tutel'ian et al.
(1999)
1.25 g/rat/day
of GM soy (RR soy)
5 months To investigate the blood,
urea and liver of animals
fed GM soy
Not stated No histopathology performed NA
Teshima et al.
(2000)
30% GM soy 15 weeks Study of the immune
system of rats and mice
5 Payer's patches collected for histopathology,
speciﬁc area of the small intestine not mentioned.
Histopathological examination of H&E stained
sections assessed structure of crypt and composition
of cells (especially goblet cells and intraepithelial
lymphocytes) according to Kawabata (1996).
However, Kawabata did not contain guidelines
as to how this assessment should be performed
and what observations would be considered to
be abnormal. No other details were provided as
to how the histopath. assessment/analysis
was performed.
No difference of crypt structure or
goblet cell frequency. Results for
intraepithelial lymphocytes were
not stated. No actual data of any
analyses were shown.
Conclusion: No diagnostically
signiﬁcant abnormalities observed
in the mucosa of the small intestine.
Tutel'ian et al.
(2001)
3 g/rat/day of GM
corn (GA21)
6 months To investigate the blood,
urea and liver of animals
fed GM corn GA21 or
GM corn MON810
Not stated No histopathology performed NA
Zhu et al. (2004) 30–90% GM soy
(RR soy)
13 weeks Nutritional assessment
and fate of DNA
10 Stomach and intestine collected for histopathology.
Sections stained with H&E and examined by
board-certiﬁed pathologist using LM. However, no
details were given as to what histopath. analyses
were performed.
Collapse of jejunum villi was observed, but
actual incidence, including incidence in
treatment and/or non-treatment group is
not reported. No actual data of any analyses
were shown.
Conclusion: No treatment related differences seen.
Hammond et al.
(2004)
11–33% GM corn
(NK603)
13 weeks General study to assess
the effect of the GM
corn on rat health
20 Stomach, duodenum, jejunum, ileum, colon, and
rectum collected for histopathology. Sections
stained with H&E and examined by a board-certiﬁed
pathologist using LM. However, no details
were given as to what histopath. analyses
were performed.
Incidence of microscopic ﬁndings was only listed
for those tissues with an incidence of 2 or more
ﬁndings. No mention of any GI tract observations.
Conclusion: According to the examining pathologist,
appearance of tissue was within normal limits.
Microscopic changes observed were those that are
typically seen in rats of this age and strain.
Modiﬁed from
OECD 408 (1981)
Sakamoto et al.
(2007)
30% GM soy
(RR soy)
26 and
52 weeks
General study to assess
the effect of the GM
soy on rat health
10 Stomach and intestines collected for histopathology.
Sections stained with H&E. However, no details
were given as to what histopath. analyses were
performed. The method used for the eosinophil and
goblet cell counts in the jejunum was described in
a table caption.
Pathological ﬁndings showed no meaningful
differences between rats fed GM or non-GM
soybeans. Relatively detailed results given for
histological ﬁndings including eosinophil and goblet
cell counts for jejunum. Gastric gland, dilatation of
slight grade was observed in all groups.
Conclusion: No obvious differences observed
between GM and non-GM fed rats.
Sakamoto et al.
(2008)
30% GM soy
(RR soy)
52 and
104 weeks
General study to assess the
effect of the GM soy on
rat health
50 Stomach and intestines collected for histopathology.
Sections stained with H&E. However, no details
were given as to what histopath. analyses
were performed.
Detailed results given of the incidence of neoplastic
and non-neoplastic lesions observed. No incidence
or increase in incidence of any speciﬁc type of
neoplastic or non-neoplastic lesions in GM fed group
in both genders and there were no lesions reported in
the GI tract.
Conclusion: No meaningful differences between rats
fed GM and non-GM soy.
Daleprane et al.
(2009)
10% GM soy 15 months
(455 days)
Nutritional study — study
of growth and haematology
of rats on GM soy, non-GM
soy or conventional diet
10 No histology performed NA
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Daleprane et al.
(2010)
10% GM soy 15 months
(455 days)
Health of the aorta of
rats on GM soy, non-GM
soy or conventional diet
10 Histology of the aorta NA
Tutel'ian et al.
(2010)
38% GM soy
(MON89788)
30 and
180 days
General study to assess
the effect of the GM
soy on rat health
50 Safety of the GM crop was examined as in
Tutel'ian et al. (2008). Review of macro- and
microscopic examinations according to textbook
guidelines (Lillie, 1969). Morphometric analysis
of the small intestine and colon performed with
the aid of computer programme AxioVision. No
other information was provided as to what other
organs were collected and what histopath. analyses
were performed.
Detailed results were given of morphometric
analysis of the small intestine, but which section
of the small intestine these results pertain to, was
not mentioned. No results given for morphometric
analysis of the colon.
Conclusion: Morphological analysis did not
reveal toxic effect of GM soy.
Seralini et al.
(2012)
11%, 22% and 30% GM
corn (NK603)
2 years General study to assess
the effect of the GM
corn on rat health
10 Oesophagus, stomach, duodenum, jejunum, ileum,
Payer's patches, and colon collected for histopathology.
Sections stained with HES. However, no details of
what histopath. analyses were performed.
Results for histopathological analysis of GI tract
were not provided.
Qi et al. (2012) 7.5%, 15% and 30% GM
soy (305423 × 40-3-2)
90 days General study to assess the
effect of the GM soy on rat health
10 Stomach, duodenum, jejunum, and ileum collected
for histopathology. Sections stained with H&E and
examined by a pathologist from the Chinese Academy
of Medical Sciences. However, no details of what
histopath. analyses were performed.
No observations or results listed for GI tract.
Conclusion: No test-substance related observations.
Cry3Bb1 and EPSPS
Healy et al.
(2008)
11–33% GM corn
(MON88017)
13 weeks General study to assess
the effect of the GM corn
on rat health
20 Stomach, duodenum, jejunum, ileum, colon, and
rectum collected for histopathology. Sections stained
with H&E and examined by board-certiﬁed veterinary
pathologist using LM. However, no details of what
histopath. analyses were performed.
Results table provided with microscopic ﬁndings,
however ﬁndings for tissues that had an incidence
of 1/20 were not reported. No mention of any GI
tract results/observations.
Conclusion: No test-article related lesions.
Modiﬁed from
OECD 408 (1998)
Tutel'ian et al.
(2008)
11 g/rat/day of GM
corn (MON88017)
30 and
180 days
General study to assess
the effect of the GM corn
on rat health
Not stated Review of macro- and microscopic examinations
according to textbook guidelines (Lillie, 1969) with
the morphometric analyses performed on the internal
organs according to Avtandilov (1982, 1990) and
Stefanov (1985). List of organs collected for histopath.
analysis was not provided.
Detailed results are given of morphometric analysis
of ileum. No mention of results for any other area
of the GI tract.
Conclusion: Morphological analysis did not
conﬁrm any toxic effect of GM corn.
Cry3Bb1
Hammond et al.
(2006b)
11–33% GM corn
(MON863)
90 days General study to assess
the effect of the GM
corn on rat health
20 Stomach, duodenum, jejunum, ileum, colon, and
rectum collected for histopathology. Histopath.
examination was performed by a pathologist at
Covance laboratories. However, no details were
provided as to what histopath. methods were used
including what stains were used and what analyses
were performed.
Parasitism was observed in the rectum and
glandular dilatation was observed in the stomach
of animals in both GM and non-GM groups. The
severity/degree of the parasitism or glandular
dilatation was not mentioned.
Conclusion: Differences if seen were not considered
to be test article related.
Modiﬁed from
OECD 408 (1981)
Cry1Ab
Noteborn et al.
(1995)
10% GM tomato
(RLE13-0009)
91 days Study to see if the Cry1Ab
protein on its own or in
the GM tomato acts on
mammals in a similar
way as on target
insect guts
12 Histological analysis was still in progress at the
time of publication.
NA
Tutel'ian et al.
(2001)
3 g/rat/day GM
corn (MON810)
6 months To investigate the blood,
urea and liver of animals
fed GM corn GA21 or
GM corn MON810
Not stated No histopathology performed NA
Wang et al.
(2002)
19–64% GM
rice (KMD1)
14 weeks
(90 days)
General study to assess
the effect of the GM rice
on rat health
20 Stomach, duodenum, jejunum, ileum, colon, and
rectum collected for histopathology. Sections were
stained with H&E. However, no details of what
histopath. analyses were performed.
No mention of any GI tract observations.
Conclusion: No toxicologically relevant changes.
(continued on next page)
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430 I.M. Zdziarski et al. / Environment International 73 (2014) 423–433other tissueswith an incidence of 1/20 are not reported.”Neither of these
papers provided a full account of pathologies present. Furthermore,
Hammond et al. (2004) do not clearly state whether “incidence” pertains
to two incidences per tissue or per rat. Such a lack of information does not
ensure that the study and its results are reproducible or even comparable.
4.4. Relevance of OECD guidelines in the evaluation of the safety of
consuming GM crops
Five of the published studies indicate that OECD 408 guidelineswere
used to assist in planning the study (Table 2). The OECD 408 guidelines
are designed to test for carcinogenicity of compounds. The guidelines
provide details on how such a feeding study should be conducted, in-
cluding information on sample size, duration etc. However, the guide-
lines do not specify the histopathological analysis that should be
performed. For example, what histopathological parameters should be
used to detect or measure the carcinogenicity of a compound. Whilst
it's our view that histopathological methods to determine carcinogenic-
ity are well established in the scientiﬁc community, the effect of GM
feed on animal health is not. In addition, the carcinogenic potential of
a GM crop is not, and should not be, the only pathology investigated.
Therefore, there is a question as to whether these OECD guidelines are
relevant to investigation of the safety of consuming GM crops. Whilst
theymaybeused as a startingpoint, it is our view that guidelines should
be established speciﬁcally for GM crops. Since GM food is considered to
be a novel food, the guidelines should list details for a thorough investi-
gation that includes a histopathological analysis of the gut and other or-
gans. In other models of GI tract damage, such as mucositis (Howarth
et al., 1996; Logan et al., 2009; Sukhotnik et al., 2008), neonatal adjust-
ment of piglets to normal diet (Godlewski et al., 2009; Strzalkowski
et al., 2007), or in gastric biopsies (Fenoglio-Preiser, 1998; Staibano
et al., 2002), the analytical method is detailed and speciﬁc, listing the
changes that need to be investigated and the microscopic techniques
and morphometric analyses that need to be used. For example, mitosis,
apoptosis and autophagy are known to be good indicators of mucosal
regeneration in the small intestine following injury. Therefore, immu-
nohistochemistry with in-tissue cytometry looking at the expression
of markers for mitosis (Ki67), apoptosis (caspase 3) and autophagy
(MAP I LC3) can be used to assess mucosal regeneration (Godlewski
et al., 2009). In mucositis-induced models, the investigation of the de-
gree of damage regularly requires not only detailed quantitative histo-
logical analyses to be conducted (Howarth et al., 1996; Logan et al.,
2009; Sukhotnik et al., 2008), but also immunohistochemistry for
markers of apoptosis (caspase 3), cell proliferation (BrdU) (Sukhotnik
et al., 2008), and pro-inﬂammatory cytokines (such as TNF, IL-1β and
IL-6) (Logan et al., 2009). Such vigorous analyses allow for a more pre-
cise assessment of possible pathological changes, whilst at the same
time decreasing the chance of subtle changes being overlooked. There-
fore, it is our view that in the investigation of the safety of GM crops on
animal and human health, such a vigorous and in-depth approach
should also be implemented.
4.5. Have enough studies been conducted to adequately state that GM crops
are safe for human and animal consumption?
Genetically modiﬁed crops have been approved for human and ani-
mal consumption for nearly 20 years (Clive and Krattiger, 1996) yet the
debate about their safety continues. Fifty-three crops are known to pos-
sess at least one of the genes investigated in this review (herbicide tol-
erance via the EPSPS gene and insect resistance via the cry1Ab or cry3Bb1
genes). Forty-seven of these crops have been approved for animal and/
or human consumption, yet published toxicity studies could be found
for only nine of these crops (19%) (Table 1). Of greater concern is that
for eight of these crops, publications appeared after the crop had been
approved for human and/or animal consumption. We understand that
other studies may exist that are commercial in conﬁdence, but these
Fig. 1. Number of publications looking at the effects of feeding rats GM crops long-term and number of event lines approved each year for human and/or animal consumption. Studies
researched the effects of ingesting GM crops that possessed the traits for herbicide tolerance (via the EPSPS gene) and insect resistance (via the cry1Ab or cry3Bb1 genes). Studies inves-
tigating the general long-term effect of GM feed on rat health are indicated in black. Other studies investigating certain speciﬁc effect of GM feed on rats are indicated in grey. Striped bars
indicate the number of GM crop event lines possessing the traits for herbicide tolerance (via the EPSPS gene) and insect resistance (via the cry1Ab or cry3Bb1 genes) that were approved
each year somewhere in the world for human and/or animal consumption.. The number of approvals per year is shown as the number above the bar. The year of approval for each event
line is only counted once, being the ﬁrst time the crop was approved somewhere in the world.
431I.M. Zdziarski et al. / Environment International 73 (2014) 423–433studies are not accessible to the scientiﬁc community. Other than the
few studies mentioned in the EFSA reports, where histopathological re-
sults were not reported, our review of the published literature wasn't
able to identify or locate any reported safety evaluations performed on
rats on these eight crops prior to their approval. Our literature reviewFig. 2. The number of approved GM crops in the world for human and/or animal consumption
effects of long-term feeding of these crops (●). Each crop was counted once when the ﬁrst st
ﬁrst approved somewhere in the world.also did not identify or locate published reports on rats for the remain-
ing 38 crops.
Thepresent review limited the search to only include feeding studies
done on rats so that the results may be comparable. It is possible that
more studies may be found if the search were to be extended to other(♦) and the number of approved GM crop lines with published studies investigating the
udy appeared investigating that crop. The year of approval is the year that the crop was
432 I.M. Zdziarski et al. / Environment International 73 (2014) 423–433animals. However, based onwhat has been found for rat studies, it is un-
likely that any additional studieswould involve a thorough safety inves-
tigation and a detailed report of all of the 47 approved GM crops
possessing one or more of the three traits. Moreover, the rat model is
the accepted OECD standard for toxicological studies of this type.
Whilst the safety of a GM crop is primarily and sometimes solely
evaluated by government food regulators using the test for substantial
equivalence, this is likely to be inadequate to fully assess the safety of
the crop for reasons stated above. Animal feeding studies provide a
more thorough method of investigating the unintended effects of the
GMprocess or the unintended effects of ingestingGMcrop components.
Animal feeding studies can identify target organs as well as predict the
chronic toxic effect of an ingested compound (OECD, 2008).
5. Conclusions
The evidence reviewed here demonstrates an incomplete picture re-
garding the toxicity (and safety) of GM crops consumed by humans and
animals. Themajority of studies reviewed lacked a uniﬁed approach and
transparency in their methodology and results, making it impossible to
properly review or repeat these studies. Furthermore, such lack of detail
makes it difﬁcult to generate evidence-based guidelines to aid in the de-
livery of an optimum safety assessment process for GM crops for animal
and human consumption.
When considering how a better risk assessment could be done, it is
important to consider systems established for other novel substances
that may generate unintended effects. For example, the registration of
pharmaceutical products requires an examination of both beneﬁts and
risks associated with their use and a complete assessment of those ben-
eﬁts and risks to establish whether the products are appropriate for
general use at a range of doses. We argue that each GM crop should
be assessed using similar methods, where a GM crop is tested in the
form and at the rates it will be consumed by animals and people.
Whilst this provides for an effective general approach, there are ad-
ditional issues for assessing GM crops that need to be taken into ac-
count. For example, the process of developing GM crops may generate
unintended effects. Furthermore, the plant developed is a novel entity
with genes, regulatory sequences and proteins that interact in complex
ways. Therefore, the resultant plant should be assessed as a whole so
that any pleiotropic effects can also be assessed. As a result, long-term
animal feeding studies should be included in risk assessments of GM
crops, together with thorough histopathological investigations using a
variety of methods to better detect subtle changes or the beginning or
presence of pathologies. Such robust and detailed studies will then
make it possible to put evidence-based guidelines in place, which will
substantially help to determine the safety of GM crops for human and
animal consumption.
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